Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, cancer and Type 1 diabetes. The IPSC news feed on Stock Titan aggregates company announcements, press releases and regulatory updates so readers can follow how Century Therapeutics communicates progress on its pipeline and corporate strategy.
According to the company’s public disclosures, key news themes include updates on clinical and preclinical programs such as CNTY-101 for B-cell-mediated autoimmune diseases, CNTY-308 as a CD19-targeted CAR-iT therapy, and CNTY-813, an iPSC-derived beta islet program for Type 1 diabetes. News items also cover scientific presentations at conferences, where Century Therapeutics shares data on Allo-Evasion™ 5.0, CAR-NK and CAR-T platforms, and iPSC-derived non-immune cell programs.
Investors and followers of IPSC can also find coverage of quarterly financial results, cash runway commentary, and organizational changes such as workforce adjustments, board appointments and executive role updates. Capital markets events, including private placement financings and participation in healthcare investment conferences, are typically disclosed through press releases and associated Form 8-K filings.
By reviewing the IPSC news stream, readers can see how Century Therapeutics describes the evolution of its iPSC cell foundry, its focus on B-cell-mediated diseases and oncology, and its efforts to advance off-the-shelf cell therapies. Bookmark this page to access a consolidated view of Century Therapeutics’ latest public communications as they are released.
Century Therapeutics (NASDAQ: IPSC) has announced key leadership changes, effective October 2024. Morgan Conn, Ph.D., has been appointed as Chief Financial Officer, bringing over 20 years of financing and business development experience in biopharma. Chad Cowan, Ph.D., a cell therapy pioneer and founder of Clade Therapeutics, will serve as Chief Scientific Officer. Both will join the Executive Committee.
The company also announced that Hy Levitsky, M.D., President of Research and Development, will transition to an advisory role. These appointments come at a important time as Century advances its clinical programs, expands into autoimmune indications, and accelerates prioritized next-generation pipeline programs.
Century Therapeutics specializes in developing induced pluripotent stem cell (iPSC)-derived cell therapies for immuno-oncology and autoimmune diseases. The company's focus includes iNK, γδ iT, and αβ iT-cell programs, combined with its Allo-Evasion™ technology.
Century Therapeutics (NASDAQ: IPSC) reported Q2 2024 financial results and business updates. Key highlights include:
1. Initiation of Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, expanding into autoimmune diseases.
2. Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101, showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas.
3. Completed dose escalation for ELiPSE-1, advancing to dose expansion in 2H 2024.
4. Q2 2024 ended with $269.6 million in cash, cash equivalents, and investments.
5. Net loss of $31.2 million for Q2 2024.
6. Full-year GAAP operating expenses expected between $150-160 million.
7. Cash runway extended into 2026.
Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study at the ASCO 2024 Annual Meeting. The study evaluates CNTY-101, an iPSC-derived NK cell therapy, in patients with relapsed or refractory non-Hodgkin lymphoma. CNTY-101 demonstrated a manageable safety profile with no dose-limiting toxicities or graft-versus-host disease and showed encouraging preliminary efficacy. The trial's novel cell-free DNA method indicates CNTY-101 persists outside the bloodstream. The study continues with dose escalation at higher levels, aiming to further validate safety and efficacy.
Century Therapeutics presented preclinical data at the ASGCT Annual Meeting, showcasing advancements in their iPSC platform technology and programs. The data highlighted the potential of their lead candidate, CNTY-101, in treating B-cell driven autoimmune diseases like SLE. Additionally, the company introduced a novel synthetic ligand targeting CD300a to prevent NK mediated rejection in allogeneic cell therapies. These developments aim to enhance the efficacy, durability, and tolerability of their iPSC candidates, offering promising treatment options across various indications.
Century Therapeutics reported its first quarter 2024 financial results, with plans to expand into additional autoimmune disease indications beyond SLE with their iPSC derived NK cell therapy, CNTY-101. They closed a $60 million private placement, acquired Clade Therapeutics to enhance their platform, and provided additional clinical data. The company ended the quarter with $249.9 million in cash, cash equivalents, and investments, with a cash runway into 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.